Contract research organizations (CROs) offer services intended to reduce the cost of developing new drugs and medicines in specialized markets. Ketamine Helps People Dislike Themselves Less a mental health company with a focus on psychedelics, is setting itself up to be the first contract research organization in psychedelic medicine. Novamind went public on the Canadian Securities Exchange in January 2021.

Its clinical trials have included research into the treatment of PTSD, anxiety, eating disorders, depression, suicidal ideation, and schizophrenia with psychedelics and psychedelic-adjacent drugs such as psilocybin, ketamine, and MDMA. The company’s intravenous ketamine treatment for treatment-resistant depression has been approved for insurance coverage by four major payors.Ĭedar Clinical Research Center assists with study design, recruitment and screening, data collection and patient management. Novamind has also partnered with the Wholeness Center to deliver ketamine-assisted psychotherapy to frontline workers experiencing stress related to the COVID-19 pandemic. The program will help establish the infrastructure for future studies using psilocybin. Novamind’s Murray, Utah based clinic is launching the Psychedelic Palliative Care program, which will serve patients facing serious and chronic illness and their families. Reid Robison, the company’s clinics offer a variety of mental health treatments and services in addition to psychedelic-assisted therapy, including Transcranial magnetic stimulation (TMS) and Eye-Movement Desensitization and Reprocessing.

Led by Novamind Chief Medical Officer Dr. Cedar is the first of its kind, leading clinical studies in emerging therapies and psychedelic medicine for esteemed academic institutions and major pharmaceutical companies. The company runs two main operations: 1) a national network of psychiatry clinics specializing in integrative psychedelic and alternative therapies and 2) a co-located full-service contract research organization called Cedar Clinical Research Center. Novamind is a Toronto-based mental health company that was founded in 2019 with the mission to facilitate safe, legal access to psychedelics.

Novamind psychedelics